This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Darbepoetin Alfa is a medication indicated to treat anaemia. It was approved for its medical use on 17th September 2001.
Mechanism of Action of undefined
Darbepoetin Alfa Injection is a biological agent that works to treat anaemia. It is produced by gene-technology in Chinese hamster ovary cells and acts in the same way as the hormone erythropoietin synthesized by the kidneys. It induces the bone marrow to produce more red blood cells and eventually reduces anaemia.
Uses of undefined
Darbepoetin Alfa Injection has been developed to treat anaemia in children and adults with chronic kidney disease (renal failure) and those receiving chemotherapy for non-bone marrow cancers.
undefined Drug administaration and Dosage available
Darbepoetin alfa is available in injection form in the doses 25mcg, 40mcg, 60mcg, 100mcg, 200mcg, 500mcg. Your physician will calculate the accurate dose after monitoring your blood counts.
For chronic renal failure, the initial recommended dose is 0.75mcg/kg bodyweight every two weeks or 0.45mcg/kg bodyweight weekly once. For patients not on dialysis the ideal dose is 1.5mcg/kg bodyweight once monthly.
For patients undergoing chemotherapy treatment, the recommended dose is 500mcg once every three weeks or 2.25mcg once weekly.
Warnings, Precautions and Side Effects of undefined
Warnings
Contact your doctor immediately if you experience shortness of breath, chest pain or excessive sweating. During the Darbepoetin Alfa injection treatment, your doctor may periodically monitor your blood parameters to prevent serious complications. Report to your doctor if you have had a history of seizures, blood pressure, sickle cell anaemia, liver disorders, hepatitis C, allergies or heart failure. Get immediate medical attention if you have any tiredness or lack of energy.
Precautions
Tell your physician if you are pregnant, breastfeeding or planning to have a baby. Darbepoetin Alfa has not been tested in pregnant or breastfeeding women, so it is advisable to exercise caution while using this injection during pregnancy or breastfeeding.
Side Effects
The common side effects that are likely to occur while you are on the treatment with Darbepoetin Alfa Injection are high blood pressure, stroke, pain at the site of injection, rash, redness, fluid retention, blood clots, etc. If you experience any allergic reactions such as excessive sweating, chest pain, tremors report to your doctor immediately.
Word Of Advice
Darbepoetin Alfa does not interfere with your ability to drive or operate machines. Your doctor will conduct blood tests regularly to determine the accurate dose and frequency at which you should take this medicine.
Frequently Asked Question
References
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Hematopoietic agents, 12th edition, 1071 - 1072.
- Amgen Europe BV, Electronic medicines compendium (EMC), [Revised on Feb 2021] [Accessed on 13th Aug 2021], https://www.medicines.org.uk/emc/files/pil.6958.pdf
- Anna Maria Libudzic-Nowak et al., Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature, Sec. Pediatric Nephrology, Published on 18th Dec 2018, Accessed on 13th Aug 2022, https://www.frontiersin.org/articles/10.3389/fped.2018.00398/full
Disclaimer
The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.